Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02486718




Registration number
NCT02486718
Ethics application status
Date submitted
4/06/2015
Date registered
1/07/2015
Date last updated
24/05/2024

Titles & IDs
Public title
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Scientific title
A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer
Secondary ID [1] 0 0
2014-003205-15
Secondary ID [2] 0 0
GO29527
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-Small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Atezolizumab
Treatment: Drugs - Cisplatin
Treatment: Drugs - Vinorelbine
Treatment: Drugs - Docetaxel
Treatment: Drugs - Gemcitabine
Treatment: Drugs - Pemetrexed

Experimental: Atezolizumab - Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed [non-squamous cell NSCLC only]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: Participants will receive atezolizumab 1200 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles and will undergo periodic chest X-ray and CT scan.

Active Comparator: Best Supportive Care - Enrollment Phase: Participants will receive four 21-day cycles of cisplatin-based chemotherapy (cisplatin plus either vinorelbine or docetaxel or gemcitabine or pemetrexed [non-squamous cell NSCLC only]), unless unacceptable toxicity, disease relapse, or participant's decision to discontinue occur. Randomization Phase: After enrollment phase participants will receive only the best supportive care and will undergo periodic chest X-ray and CT scan.


Treatment: Drugs: Atezolizumab
Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).

Treatment: Drugs: Cisplatin
Participants will receive cisplatin 75 milligrams per square meter (mg/m^2) IV on Day 1 of up to four 21-day cycles.

Treatment: Drugs: Vinorelbine
Participants will receive vinorelbine 30 mg/m^2 IV on Days 1 and 8 of each of the four 21-day cycles.

Treatment: Drugs: Docetaxel
Participants will receive docetaxel 75 mg/m^2 IV on Day 1 of each of the four 21-day cycles.

Treatment: Drugs: Gemcitabine
Participants will receive gemcitabine 1250 mg/m^2 IV on Days 1 and 8 of each of the four 21-day cycles.

Treatment: Drugs: Pemetrexed
Participants will receive pemetrexed 500 mg/m^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Disease-Free Survival (DFS), Assessed Using Computed Tomography (CT)/Magnetic Resonance Imaging (MRI)/X-Ray
Timepoint [1] 0 0
From randomization to the date of first recurrence of NSCLC, occurrence of new primary NSCLC, or death from any cause, whichever occurs first (up to approximately 131 months)
Secondary outcome [1] 0 0
Overall Survival (OS) in the ITT Population
Timepoint [1] 0 0
Baseline up to death from any cause (up to approximately 131 months)
Secondary outcome [2] 0 0
Percentage of Participants Who are Disease-Free at Year 3, Assessed Using CT/MRI/X-Ray
Timepoint [2] 0 0
Year 3
Secondary outcome [3] 0 0
Percentage of Participants Who are Disease-Free at Year 5, Assessed Using CT/MRI/X-Ray
Timepoint [3] 0 0
Year 5
Secondary outcome [4] 0 0
DFS Within Selected Populations
Timepoint [4] 0 0
From randomization to the date of first recurrence of NSCLC, occurrence of new primary NSCLC, or death from any cause, whichever occurs first (up to approximately 67 months)
Secondary outcome [5] 0 0
Percentage of Participants with Adverse Events
Timepoint [5] 0 0
Baseline up to approximately 131 months
Secondary outcome [6] 0 0
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab
Timepoint [6] 0 0
Predose (Hour 0) on Day (D) 1 of Cycles (Cy) 1, 2, 3, 4, 8, 16 (Cy length=21 days), at treatment discontinuation (TD) (up to 12 months), 120 days after last atezolizumab administration (up to 16 months)
Secondary outcome [7] 0 0
Maximum Plasma Concentration (Cmax) of Atezolizumab
Timepoint [7] 0 0
Post-infusion on Day 1 of Cycle 1 (cy length = 21 days)
Secondary outcome [8] 0 0
Minimum Serum Concentration (Cmin) at Steady-State Within a Dosing Interval of Atezolizumab
Timepoint [8] 0 0
Prior to infusion on D1 of Cy2, 3, 4, 8, 16 (Cy length = 21 days), and at study termination (up to approximately 131 months)

Eligibility
Key inclusion criteria
Inclusion Criteria for Enrollment Phase

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Histological or cytological diagnosis of Stage IB (tumors greater than or equal to
[>/=] 4 centimeters [cm])-IIIA (T2-3 N0, T1-3 N1, T1-3 N2, T4 N0-1) NSCLC (per the
Union Internationale Contre le Cancer staging system (UICC)/American Joint Committee
on Cancer staging system (AJCC) staging system, 7th edition; Detterbeck et al. 2009)

- Participants must have had complete resection of NSCLC 4-12 weeks (>/=28 days and less
than or equal to [</=] 84 days) prior to enrollment and must be adequately recovered
from surgery

- If mediastinoscopy was not performed preoperatively, it is required that, at a
minimum, mediastinal lymph node systematic sampling will have occurred. Systematic
sampling is defined as removal of at least one representative lymph node at specified
levels. MLND entails resection of all lymph nodes at those same levels. For a right
thoracotomy, sampling or MLND is required at levels 4 and 7 and for a left
thoracotomy, levels 5 and/or 6 and 7. Exceptions will be granted if there is clear
documentation in the operative report or in a separately submitted addendum by the
surgeon of exploration of the required lymph node areas, the participant will be
considered eligible if no lymph nodes are found in those areas; if participants have
documented N2 disease in one level (per the UICC/AJCC staging system, 7th edition;
Detterbeck et al. 2009), not all levels need to be sampled; if the preoperative
staging imaging results (contrast computed tomography [CT] and positron emission
tomography [PET] scans) do not suggest evidence of disease in the mediastinum, the
participant will be considered eligible if N2 nodal sampling is not performed per
surgeon's decision

- Eligible to receive a cisplatin-based chemotherapy regimen

- Adequate hematologic and end-organ function

- Women who are not postmenopausal (>/=12 months of non-therapy-induced amenorrhea) or
surgically sterile must have a negative serum pregnancy test result within 14 days
prior to initiation of cisplatin-based chemotherapy

Inclusion Criteria for Randomized Phase - Women who are not postmenopausal (>/=12 months of
non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy
test result within 14 days prior to initiation of atezolizumab or BSC
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria for Enrollment Phase

- Illness or condition that may interfere with a participant's capacity to understand,
follow, and/or comply with study procedures

- Pregnant and lactating women

- Treatment with prior systemic chemotherapy: Chemotherapy for early stage of malignancy
with curative intent, provided that the last dose received was more than 5 years prior
to enrollment and low-dose chemotherapy for non-malignant conditions may be allowed
upon approval by the Medical Monitor

- Hormonal cancer therapy or radiation therapy as prior cancer treatment within 5 years
before enrollment

- Treatment with any other investigational agent with therapeutic intent within 28 days
prior to enrollment

- Participants with hearing impairment

- Known sensitivity to any component of the chemotherapy regimen the participant will be
assigned to, or to mannitol

- Prior treatment with cluster of differentiation (CD) 137 (CD137) agonists or immune
checkpoint blockade therapies, anti-programmed death-1 (PD-1), and anti programmed
death ligand 1 (PD-L1) therapeutic antibodies

- Malignancies other than NSCLC within 5 years prior to randomization, with the
exception of those with a negligible risk of metastasis or death (e.g., expected
5-year OS greater than [>] 90 percent [%]) treated with expected curative outcome
(such as adequately treated carcinoma in situ of the cervix, basal or squamous cell
skin cancer, localized prostate cancer treated surgically with curative intent, ductal
carcinoma in situ treated surgically with curative intent)

- History of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric or humanized antibodies or fusion proteins

- Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells
or any component of the atezolizumab formulation

- History of autoimmune disease, including but not limited to myasthenia gravis,
myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,
inflammatory bowel disease, vascular thrombosis associated with antiphospholipid
syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome,
multiple sclerosis, vasculitis, or glomerulonephritis

- Positive test for human immunodeficiency virus (HIV)

- Participants with active hepatitis B (chronic or acute; defined as having a positive
hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C

- Active tuberculosis

- Significant cardiovascular disease, such as New York Heart Association cardiac disease
(Class II or greater), myocardial infarction, or cerebrovascular accident within the
previous 3 months, unstable arrhythmias, or unstable angina

- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis
obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active
pneumonitis on screening chest CT scan

- Prior allogeneic bone marrow transplantation or solid organ transplant

- Any other diseases, metabolic dysfunction, physical examination finding, or clinical
laboratory finding giving reasonable suspicion of a disease or condition that
contraindicates the use of an investigational drug or that may affect the
interpretation of the results or render the participant at high risk from treatment
complications

- Known tumor PD-L1 expression status as determined by an immunohistochemistry (IHC)
assay from other clinical studies (e.g., participants whose PD-L1 expression status
was determined during screening for entry into a study with anti-PD-1 or anti-PD-L1
antibodies but were not eligible are excluded)

Specific Exclusions for Pemetrexed Treatment

- Participants with squamous cell histology

Exclusion Criteria for Randomized Phase

- Signs or symptoms of infection within 14 days prior to randomization (severe infection
within 28 days prior to randomization), including but not limited to hospitalization
for complications of infection, bacteremia, or severe pneumonia

- Received therapeutic oral or intravenous (IV) antibiotics within 14 days prior to
randomization

- Major surgical procedure within 28 days prior to randomization or anticipation of need
for a major surgical procedure during the course of the study

- Administration of a live, attenuated vaccine within 4 weeks prior to initiation of
study treatment or anticipation that such a live attenuated vaccine will be required
during the study

- Treatment with systemic immunostimulatory agents (including but not limited to
interferons or interleukin-2) within 4 weeks or 5 half-lives of the drug, whichever is
longer, prior to randomization: Prior treatment with cancer vaccines is allowed

- Treatment with systemic corticosteroids or other immunosuppressive medications
(including but not limited to prednisone, dexamethasone, cyclophosphamide,
azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF]
agents) within 14 days prior to randomization

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
31/10/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/08/2035
Actual
Sample size
Target
Accrual to date
Final
1280
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
Townsville Hospital - Townsville
Recruitment hospital [2] 0 0
Cabrini Hospital Malvern - Malvern
Recruitment postcode(s) [1] 0 0
4810 - Townsville
Recruitment postcode(s) [2] 0 0
3144 - Malvern
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Kentucky
Country [8] 0 0
United States of America
State/province [8] 0 0
Maine
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Mississippi
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Nevada
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oregon
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
Rhode Island
Country [20] 0 0
United States of America
State/province [20] 0 0
South Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Tennessee
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Virginia
Country [24] 0 0
United States of America
State/province [24] 0 0
Washington
Country [25] 0 0
Belgium
State/province [25] 0 0
Bruxelles
Country [26] 0 0
Belgium
State/province [26] 0 0
Liège
Country [27] 0 0
Canada
State/province [27] 0 0
Ontario
Country [28] 0 0
Canada
State/province [28] 0 0
Quebec
Country [29] 0 0
China
State/province [29] 0 0
Beijing
Country [30] 0 0
China
State/province [30] 0 0
Guangdong
Country [31] 0 0
China
State/province [31] 0 0
Guangzhou
Country [32] 0 0
China
State/province [32] 0 0
Hefei City
Country [33] 0 0
China
State/province [33] 0 0
Shanghai
Country [34] 0 0
China
State/province [34] 0 0
Shengyang
Country [35] 0 0
China
State/province [35] 0 0
Shenyang
Country [36] 0 0
China
State/province [36] 0 0
Suzhou
Country [37] 0 0
China
State/province [37] 0 0
Zhejiang
Country [38] 0 0
France
State/province [38] 0 0
Limoges
Country [39] 0 0
France
State/province [39] 0 0
Lyon
Country [40] 0 0
France
State/province [40] 0 0
Marseille
Country [41] 0 0
France
State/province [41] 0 0
Mont De Marsan
Country [42] 0 0
France
State/province [42] 0 0
Montpellier
Country [43] 0 0
France
State/province [43] 0 0
Nantes
Country [44] 0 0
France
State/province [44] 0 0
Saint Pierre
Country [45] 0 0
France
State/province [45] 0 0
Saint-Mande
Country [46] 0 0
France
State/province [46] 0 0
Saint-Quentin
Country [47] 0 0
France
State/province [47] 0 0
Toulon
Country [48] 0 0
Germany
State/province [48] 0 0
Berlin
Country [49] 0 0
Germany
State/province [49] 0 0
Bielefeld
Country [50] 0 0
Germany
State/province [50] 0 0
Braunschweig
Country [51] 0 0
Germany
State/province [51] 0 0
Chemnitz
Country [52] 0 0
Germany
State/province [52] 0 0
Frankfurt am Main
Country [53] 0 0
Germany
State/province [53] 0 0
Großhansdorf
Country [54] 0 0
Germany
State/province [54] 0 0
Halle
Country [55] 0 0
Germany
State/province [55] 0 0
Hamburg
Country [56] 0 0
Germany
State/province [56] 0 0
Heidelberg
Country [57] 0 0
Germany
State/province [57] 0 0
Hemer
Country [58] 0 0
Germany
State/province [58] 0 0
Homburg
Country [59] 0 0
Germany
State/province [59] 0 0
Immenhausen
Country [60] 0 0
Germany
State/province [60] 0 0
Karlsruhe
Country [61] 0 0
Germany
State/province [61] 0 0
Koblenz Am Rhein
Country [62] 0 0
Germany
State/province [62] 0 0
Koln
Country [63] 0 0
Germany
State/province [63] 0 0
Löwenstein
Country [64] 0 0
Germany
State/province [64] 0 0
München
Country [65] 0 0
Germany
State/province [65] 0 0
Münster
Country [66] 0 0
Germany
State/province [66] 0 0
Oldenburg
Country [67] 0 0
Germany
State/province [67] 0 0
Regensburg
Country [68] 0 0
Germany
State/province [68] 0 0
Velbert
Country [69] 0 0
Hong Kong
State/province [69] 0 0
Shatin
Country [70] 0 0
Hungary
State/province [70] 0 0
Budapest
Country [71] 0 0
Hungary
State/province [71] 0 0
Pecs
Country [72] 0 0
Hungary
State/province [72] 0 0
Szolnok
Country [73] 0 0
Hungary
State/province [73] 0 0
Törökbálint
Country [74] 0 0
Israel
State/province [74] 0 0
Haifa
Country [75] 0 0
Israel
State/province [75] 0 0
Holon
Country [76] 0 0
Israel
State/province [76] 0 0
Kfar-Saba
Country [77] 0 0
Israel
State/province [77] 0 0
Petach Tikva
Country [78] 0 0
Israel
State/province [78] 0 0
Ramat Gan
Country [79] 0 0
Israel
State/province [79] 0 0
Tel Aviv
Country [80] 0 0
Italy
State/province [80] 0 0
Abruzzo
Country [81] 0 0
Italy
State/province [81] 0 0
Friuli-Venezia Giulia
Country [82] 0 0
Italy
State/province [82] 0 0
Lazio
Country [83] 0 0
Italy
State/province [83] 0 0
Lombardia
Country [84] 0 0
Italy
State/province [84] 0 0
Piemonte
Country [85] 0 0
Italy
State/province [85] 0 0
Sicilia
Country [86] 0 0
Italy
State/province [86] 0 0
Toscana
Country [87] 0 0
Italy
State/province [87] 0 0
Trentino-Alto Adige
Country [88] 0 0
Italy
State/province [88] 0 0
Umbria
Country [89] 0 0
Italy
State/province [89] 0 0
Veneto
Country [90] 0 0
Japan
State/province [90] 0 0
Aichi
Country [91] 0 0
Japan
State/province [91] 0 0
Chiba
Country [92] 0 0
Japan
State/province [92] 0 0
Ehime
Country [93] 0 0
Japan
State/province [93] 0 0
Fukuoka
Country [94] 0 0
Japan
State/province [94] 0 0
Hiroshima
Country [95] 0 0
Japan
State/province [95] 0 0
Hokkaido
Country [96] 0 0
Japan
State/province [96] 0 0
Hyogo
Country [97] 0 0
Japan
State/province [97] 0 0
Kanagawa
Country [98] 0 0
Japan
State/province [98] 0 0
Kitakyushu-shi
Country [99] 0 0
Japan
State/province [99] 0 0
Kumamoto
Country [100] 0 0
Japan
State/province [100] 0 0
Kyoto
Country [101] 0 0
Japan
State/province [101] 0 0
Miyagi
Country [102] 0 0
Japan
State/province [102] 0 0
Niigata
Country [103] 0 0
Japan
State/province [103] 0 0
Okayama
Country [104] 0 0
Japan
State/province [104] 0 0
Saitama
Country [105] 0 0
Japan
State/province [105] 0 0
Shizuoka
Country [106] 0 0
Japan
State/province [106] 0 0
Tokyo
Country [107] 0 0
Japan
State/province [107] 0 0
Wakayama
Country [108] 0 0
Korea, Republic of
State/province [108] 0 0
Jeollanam-do
Country [109] 0 0
Korea, Republic of
State/province [109] 0 0
Suwon-si
Country [110] 0 0
Netherlands
State/province [110] 0 0
'S Hertogenbosch
Country [111] 0 0
Netherlands
State/province [111] 0 0
Groningen
Country [112] 0 0
Netherlands
State/province [112] 0 0
Nieuwegein
Country [113] 0 0
Poland
State/province [113] 0 0
Otwock
Country [114] 0 0
Poland
State/province [114] 0 0
Poznan
Country [115] 0 0
Portugal
State/province [115] 0 0
Coimbra
Country [116] 0 0
Portugal
State/province [116] 0 0
Lisboa
Country [117] 0 0
Portugal
State/province [117] 0 0
Porto
Country [118] 0 0
Romania
State/province [118] 0 0
Craiova
Country [119] 0 0
Russian Federation
State/province [119] 0 0
Mordovija
Country [120] 0 0
Russian Federation
State/province [120] 0 0
Moskovskaja Oblast
Country [121] 0 0
Russian Federation
State/province [121] 0 0
Sankt Petersburg
Country [122] 0 0
Russian Federation
State/province [122] 0 0
Tatarstan
Country [123] 0 0
Russian Federation
State/province [123] 0 0
Novosibirsk
Country [124] 0 0
Russian Federation
State/province [124] 0 0
Volgograd
Country [125] 0 0
Russian Federation
State/province [125] 0 0
Yaroslavl
Country [126] 0 0
Spain
State/province [126] 0 0
Barcelona
Country [127] 0 0
Spain
State/province [127] 0 0
Cantabria
Country [128] 0 0
Spain
State/province [128] 0 0
Castellon
Country [129] 0 0
Spain
State/province [129] 0 0
Islas Baleares
Country [130] 0 0
Spain
State/province [130] 0 0
LA Coruña
Country [131] 0 0
Spain
State/province [131] 0 0
Murcia
Country [132] 0 0
Spain
State/province [132] 0 0
Tenerife
Country [133] 0 0
Spain
State/province [133] 0 0
Cordoba
Country [134] 0 0
Spain
State/province [134] 0 0
Jaen
Country [135] 0 0
Spain
State/province [135] 0 0
Lugo
Country [136] 0 0
Spain
State/province [136] 0 0
Madrid
Country [137] 0 0
Spain
State/province [137] 0 0
Valencia
Country [138] 0 0
Spain
State/province [138] 0 0
Zaragoza
Country [139] 0 0
Taiwan
State/province [139] 0 0
Chang Hua
Country [140] 0 0
Taiwan
State/province [140] 0 0
Kaohsiung City
Country [141] 0 0
Taiwan
State/province [141] 0 0
Liuying Township
Country [142] 0 0
Taiwan
State/province [142] 0 0
Putzu
Country [143] 0 0
Taiwan
State/province [143] 0 0
Taipei City
Country [144] 0 0
Taiwan
State/province [144] 0 0
Taipei
Country [145] 0 0
Taiwan
State/province [145] 0 0
Taoyuan City
Country [146] 0 0
Taiwan
State/province [146] 0 0
Xitun Dist.
Country [147] 0 0
Ukraine
State/province [147] 0 0
Katerynoslav Governorate
Country [148] 0 0
Ukraine
State/province [148] 0 0
Kharkiv Governorate
Country [149] 0 0
Ukraine
State/province [149] 0 0
KIEV Governorate
Country [150] 0 0
Ukraine
State/province [150] 0 0
Poltava Governorate
Country [151] 0 0
Ukraine
State/province [151] 0 0
Kirovograd
Country [152] 0 0
Ukraine
State/province [152] 0 0
Kryvyi Rih
Country [153] 0 0
Ukraine
State/province [153] 0 0
Kyiv
Country [154] 0 0
Ukraine
State/province [154] 0 0
Sumy
Country [155] 0 0
Ukraine
State/province [155] 0 0
Zaporizhzhya
Country [156] 0 0
United Kingdom
State/province [156] 0 0
Birmingham
Country [157] 0 0
United Kingdom
State/province [157] 0 0
Colchester, Essex
Country [158] 0 0
United Kingdom
State/province [158] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase III, global, multicenter, open-label, randomized study to compare the
efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A)
treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA
non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured
by disease-free survival (DFS) as assessed by the investigator and overall survival (OS).
Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will
be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02486718
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02486718